CEO Michael Mahoney expands his equity position by 13% with a $10 million share buy amid a 54% stock decline over the past year.
Boston Scientific CEO Michael Mahoney acquired 208,000 shares for $10 million at an average price of $48.34 on August 3, 2026. The purchase increases his total holdings to 1.6 million shares, valued at $78.08 million based on the market close.
The transaction follows a 54% decline in Boston Scientific’s stock over the prior 12 months. Shares were bought at prices ranging from $47.87 to $48.47, with most executed as direct purchases and a portion through a 401(k) plan rebalancing.
Mahoney’s expanded stake represents a 13% increase in his equity position, signaling confidence amid recent underperformance.